Researchers from Sant Pau have published an article in Frontiers in Medicine (journal of the first quartile of the Internal Medicine area) where they analyse the incidence and predictive factors of pulmonary embolisms or thrombosis in patients hospitalised with Covid-19. The research has concluded that the incidence of 2.6% of pulmonary embolisms or thrombosis in patients hospitalized with Covid-19 is clearly high.
Researchers from the Clinical Epidemiology and Health Services Research Group of the Sant Pau Research Institute -IIB, led by Laura Martínez, together with the updating working group of the Guideline International Network and other collaborators, have developed an “UpPriority” tool that provides a simple prioritisation strategy to determine which clinical questions included in a CPG need to be preferentially updated, as detailed by the authors in a recent article published in the Journal of Clinical Epidemiology.
La Dra. Lorena Alba Castellón, del Grupo de Investigación de Oncogénesis y Antitumorales del Instituto de Investigación del Hospital de Sant Pau – IIB Sant Pau, ha obtenido una ayuda postdoctoral de la Asociación Española Contra el Cáncer (AECC) para su proyecto Cancer Associated Firbroblast-Tarageted Nanoparticles to Improve Antimetastastic Therapyn Colorectal Cancer. Esta ayuda ha sido entregada por la AECC con motivo del Día Mundial de la Investigación en Cáncer (World Cancer Research Day) que se celebra el 24 de septiembre.
New research has shown that virgin olive oil enriched with its own phenolic compounds increases the ability of HDL particles (high-density lipoproteins) to transport cholesterol deposited on the arterial wall for subsequent elimination from the body, through the liver and intestine. The work, published in the journal Biomedicines, has been coordinated by researchers from CIBER in the areas of Diabetes and Associated Metabolic Diseases (CIBERDEM) and Physiopathology of Obesity and Nutrition (CIBEROBN), the Research Institute and Hospital de la Santa Creu i Sant Pau, the Hospital del Mar Institute for Medical Research (IMIM), Rovira i Virgili University, the University of Lleida and the Institute of Vine and Wine Sciences-ICVV.
Reference article: https://www.mdpi.com/2227-9059/8/8/266
The Research Institute of the Hospital de Sant Pau – IIB Sant Pau participates in a study published in the journal Science that reveals that biological sex has a small but widespread influence on the gene expression of almost every type of human tissue. Genes that are estimated to be expressed at different levels in adult women and men are involved in many different biological processes, including response to medication, control of blood glucose levels during pregnancy, and cancer.
Reference article: https://doi.org/10.1126/science.aba3066
M. Rosa Ballester Verneda, researcher at the Drug Research Center (CIM), has recently been elected Research and Teaching Member of the Governing Board of the Barcelona College of Pharmacists.
A study led by Dr. Pere Domingo, coordinator of the HIV and AIDS Research Group and hospitalization COVID of the Sant Pau Research Institute -IIB Sant Pau and member of the Infectious Diseases Unit of the Hospital de Sant Pau analyzes the pathogenesis of COVID -19 as the dynamic interaction between four circles that occur simultaneously. One more step to understand the mechanism that the virus uses to bypass the host’s immune defense mechanisms, or the mechanisms it uses to harm, and that will allow designing appropriate strategies to neutralize the dysfunctions or imbalances generated by the virus or by the consequences of the infection.
Thanks to the work coordinated by Dra. Maria Pía Gallano, director of the Genetic Diseases Research Group at the Sant Pau Research Institute, in which researchers from various centers also affiliated to CIBERER have participated, has designed a genetic panel of mass sequencing (NGS) with great power diagnosis for people affected by neuromuscular diseases such as myopathies, muscular dystrophies, and previously undiagnosed congenital myasthenic syndromes.
See more
With this NGS panel, they analyzed a cohort of 207 patients in Spain and detected the cause of the disease in 102, 49% of them, in 42 genes. Thus, this panel is constituted as a tool for the analysis of genes related to neuromuscular diseases that offers reliable results in a short period of time and relegates invasive techniques to later stages. The work has been published in the journal Genes.
More information
The Fundació Institut de Recerca del Hospital de la Santa Creu i Sant Pau has recently become a member of the Bioinformatics Barcelona Association (BIB), a non-profit association for education and training, promoting advanced research , knowledge and technology transfer, stimulating competitiveness and innovation within the industrial sector, and providing greater international visibility in the field of bioinformatics.
The Foundation of the Research Institute of the Hospital de la Santa Creu i Sant Pau joins the Aliança Instituts de Recerca i Innovació en salut de Catalunya (IRISCAT). The main objectives of this agreement are the creation of a cooperative workspace that operates under the name IRISCAT to better take advantage of the advantages conferred by the dimension and high level of standards of the healthcare and research organization in which they operate, with the vision of improving the translational and clinical research of the Catalan Health System; also the preparation of a strategic Plan for its development that considers the needs and implications necessary for its implementation and the achievement of the objective of exploitation and integration of economies of scale in the different fields of action and the creation of a Technical Office, with the objective to coordinate the implementation of the execution process of the actions contemplated in the Strategic Plan of the IRISCAT Alliance.
Exheus is a recent spin-off born thanks to the research carried out by the Sant Pau Research Institute, the Polytechnic University of Catalonia – BarcelonaTech (UPC) and the company Summit SL, which has introduced into the market an innovative technology that analyses gene expression and its alterations, through artificial intelligence, to optimise people’s performance, health and nutrition. The spin-off has been set up within the framework of the Venture Builder ‘The Collider’ programme of the Mobile World Capital Barcelona Foundation.
Geneticists from the Research Institute of the Hospital de Sant Pau – IIB Sant Pau and the IFOM – Instituto FIRC di Oncologia Molecolare of Milan (Italy), led by doctors Jordi Surrallés and Paolo Peterlongo respectively, have discovered that certain rare mutations in the FANCM gene constitute a predisposition factor for developing ER and triple-negative breast cancer, considered to be the most aggressive and with the worst prognosis among the different types of breast cancer.
The CERCA system is committed to the equality of people and the maximum respect for their different situations and wants to improve the current situation for people and research institutions. The I-CERCA, through its gender commission, is a beneficiary of aid from the State Pact against Gender Violence, which is granted by the Ministry of the Presidency, Relations with the Courts and Equality.
Under these grants, since 2019, a series of tools and training and awareness actions against gender violence have been developed in the academic environment, and specifically for research centres, such as the current video that you can see in more.
You can see the entire video at this link:
Acute myeloid leukemia is a very heterogeneous disease, the usual treatment is very aggressive and with severe side effects. In the investigation of a new, more effective drug, researchers led by the Oncogenesis and Antitumoral Research Group of the Sant Pau Hospital Research Institute – IIB Sant Pau (Ramon Mangues, Isolda Casanova and Víctor Pallarès) attached to the CIBER-BBN, have demonstrated the efficacy of the self-created nanoparticle that blocks the spread of leukemia cells in animal models of acute myeloid leukemia and directly attacks tumor cells without damaging healthy ones, minimizing adverse effects.
We now have the results of the study that analyses the impact of advertising related to gambling carried out at the Sant Pau. The study has been led by Dr. Marta Sancho, from the Addictive Behaviour Research Group of the Sant Pau Research Institute-IIB Sant Pau and clinical psychologist of the Addictive Behaviour Unit of the Sant Pau Psychiatry Service and was awarded a prize at the 4th ONCE International Competition on Responsible Gambling.
Acute myeloid leukemia is a very heterogeneous disease, the usual treatment is very aggressive and with severe side effects. In the investigation of a new, more effective drug, researchers led by the Oncogenesis and Antitumoral Research Group of the Sant Pau Hospital Research Institute – IIB Sant Pau (Ramon Mangues, Isolda Casanova and Víctor Pallarès) attached to the CIBER-BBN, have demonstrated the efficacy of the self-created nanoparticle that blocks the spread of leukemia cells in animal models of acute myeloid leukemia and directly attacks tumor cells without damaging healthy ones, minimizing adverse effects.
Patricia Cancelo, sculptor, painter and journalist, has donated a collection of sculptures and paintings, valued at 10,000 euros, to the Sant Pau, in order to start two research projects in the field of pregnancy, childbirth and postpartum in women affected by Covid-19. These two studies are part of the more than 30 works initiated by the Sant Pau Research Institute in the field of Covid-19.
The Berlin State Senate, at the proposal of the Mayor of this city and the Senator for Science and Research, Michael Müller, recently appointed Lina Badimon, director of the “ICCC Cardiovascular Program” of the Sant Pau-IIB Sant Pau Research Institute and group leader of the CIBERCV, as a new Member of the Supervisory Board of the Berlin Health Institute (BIH Supervisory Board).
One of the world’s leading medical journals, The Lancet, published the article ‘Clinical and biomarker changes of Alzheimer’s disease in adults with Down syndrome: a cross-sectional study’, led by the Alzheimer-Down Unit of Hospital de la Santa Creu i Sant Pau and the Fundación Catalana Síndrome de Down, in collaboration with researchers of the University of Cambridge, United Kingdom, promoted by Fundació “la Caixa”.
Researchers in the research group on the Metabolic Basis of Cardiovascular Risk at the Sant Pau Research Institute, attached to CIBERDEM, led by Juan Carlos Escolà-Gil and Francisco Blanco-Vaca, have identified a new metabolic pathway that allows HDLs to transport cholesterol from macrophages in the artery wall and transfer it to LDLs for its subsequent elimination from the body through the liver. The work carried out in collaboration with other Spanish and Finnish researchers has been published in Circulation Research.
